Trends in mortality and morbidity of bullous pemphigoid before and after approval of intravenous immunoglobulin in Japan: An interrupted time-series analysis.
Hideaki MiyachiTakaaki KonishiYohei HashimotoHiroki MatsuiKiyohide FushimiTakashi InozumeHiroyuki MatsueHideo YasunagaPublished in: Clinical and experimental dermatology (2023)
IVIg approval is associated with lower in-hospital mortality and morbidity in inpatients with bullous pemphigoid.